Abbott links up with Advanced Life Science Institute (ALSI) on ProGRP (Pro-gastrin-releasing peptide) lung cancer test agreement:
This article was originally published in Clinica
Abbott Diagnostics has obtained worldwide rights to commercialise products using Advanced Life Science Institute's (ALSI) Pro-gastrin-releasing peptide (ProGRP) biomarker, which could be used to earlier diagnose small cell lung cancer. Abbott plans to use ProGRP to widen the menu on one of its analysers, most likely a menu from its Architect, or AxSYM range, said the firm. ProGRP has shown promise in preliminary studies as a test for lung cancer. "Through automation, this marker could be further refined for clinical use," commented William Brown, Abbott's vice-president of diagnostic assays and systems development. ALSI, based in Saitama, Japan, hopes that the agreement will enable its tumour maker technology to "reach a wider audience".